TAILIEUCHUNG - Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer

• Menopausal hormone therapy: Some studies have suggested that women who take estrogen by itself (estrogen without progesterone) for 10 or more years may have an increased risk of ovarian cancer. Scientists have also studied whether taking certain fertility drugs, using talcum powder, or being obese are risk factors. It is not clear whether these are risk factors, but if they are, they are not strong risk factors. Having a risk factor does not mean that a woman will get ovarian cancer. Most women who have risk factors do not get ovarian cancer. On the other hand, women who do get the disease often have no known risk factors, except for. | Issue date January 2007 Review date May 2009 Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer National Institute for Health and Clinical Excellence NHS NICE technology appraisal guidance 118 NICE technology appraisal guidance 118 Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer Ordering information You can download the following documents from TA118 The full guidance this document . A quick reference guide for healthcare professionals. Information for people with metastatic colorectal cancer and their carers Understanding NICE guidance . Details of all the evidence that was looked at and other background information. For printed copies of the quick reference guide or Understanding NICE guidance phone the NHS Response Line on 0870 1555 455 and quote N1199 quick reference guide N1200 Understanding NICE guidance . This guidance is written in the following context This guidance represents the view of the Institute which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. The guidance does not however override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient in consultation with the patient and or guardian or carer. National Institute for Health and Clinical Excellence MidCity Place 71 High Holborn London WC1V 6NA National Institute for Health and Clinical Excellence January 2007. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations or for commercial purposes is allowed without the express written permission of the Institute. Contents 1 Guidance 4 2 Clinical need and practice 4 3 The technologies 6 4 Evidence and interpretation 8 5 Implementation 23 6 Recommendations for .

• Y học thường thức
• Progesterone Resistance
• Resistance and Targeting
• Progesterone Receptors
• Therapeutic Approach
• Approach to Endometriosis
• Endometriosis
• Involvement
• Prostaglandins
• Pathophysiology of Endometriosis